Adjunctive topiramate treatment in refractory obese bipolar patients: A descriptive open label study

Eating and Weight Disorders

Volumn 12, Issue 1, 2007, Pages 48-53

  Gabriel, Adel ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Bipolar disorder; Mixed; Obesity; Rapid cycling; Refractory; Topiramate

Indexed keywords

AMFEBUTAMONE; GABAPENTIN; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE; ANTIOBESITY AGENT; DRUG DERIVATIVE; FRUCTOSE;

ADD ON THERAPY; ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; HAMILTON SCALE; HAND PARESTHESIA; HUMAN; MALE; MENTAL CONCENTRATION; MOTOR DYSFUNCTION; OBESITY; OPEN STUDY; RATING SCALE; SIDE EFFECT; TREATMENT RESPONSE; VISUAL DISORDER; WEIGHT CHANGE; WEIGHT REDUCTION; DRUG RESISTANCE; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; ANTI-OBESITY AGENTS; BIPOLAR DISORDER; DRUG RESISTANCE; FEMALE; FRUCTOSE; HUMANS; MALE; OBESITY; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 33947720723     PISSN: 11244909     EISSN: 15901262     Source Type: Journal    
DOI: 10.1007/BF03327772     Document Type: Article

References (40)

1. Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., Pope H.G. Jr, Chou J.C., Keck P.E. Jr, Rhodes L.J., Swann A.C., Hirschfeld R.M., Wozniak P.J.: A randomised placebo-controlled 12 months trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry, 57, 481-489, 2000.
2. Chengappa R.K.N., Gershon S., Levine J.: The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disorders, 3, 215-232, 2001.
3. Thase M.E., Sachs G.S.: Bipolar depression, pharmacotherapy and related therapeutic strategies. Biol. Psychiatry, 48, 558-572, 2000.
4. Dunn R.T., Frye M.S., Kimbrell T.A., Denicoff K.D., Leverich G.S., Post R.M.: The efficacy and use of anticonvulsants in mood disorders. Clin. Neuropharmacol., 21, 215-235, 1998.
5. Dubovsky S.L., Buzan R.D.: Novel alternatives and supplements to lithium and anticonvulsants for Bipolar Affective Disorder. J. Clin. Psychiatry, 58, 224-242, 1997.
6. Nemeroff C.B.: An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J. Clin. Psychiatry, 13 (Suppl. 61), 19-25, 2000.
7. Vieta E., Sanchez-Moreno J., Goikolea J.M., Colom F., Martinez-Aran A., Benabarre A., Corbella B., Torrent C., Comes M., Reinares M., Brugue E.: Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J. Clin. Psychopharmacol., 24, 374-378, 2004.
8. Ketter T.A., Wang P.W., Tate D.L., Rennicke C.M., Hier A.M., Strong C.M.: Low dose adjunctive topiramate attenuates weight gain in bipolar disorder patients. The international J. Neuropsychopharmacol., 3 (Suppl. 1), S344, 2000.
9. Garonna F., Stifani L.: Topiramate in the treatment of overweight/obese binge eaters. Int. J. Neuropsychopharmacol., 3, S299, 2000.
10. Bahk W.M., Shin Y.C., Woo J.M., Yoon B.H., Lee J.S., Jon D.I., Chung S.K., Choi S.K., Paik I.H., Pae C.U.: Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 29, 115-121, 2005.
11. Marken P.A., Pies R.W.: Emerging treatments for bipolar disorder: safety and adverse effect profiles. Ann. Pharmacother., 40, 276-285, 2006, Epub 2006 Jan.
12. Calabrese J.R., Keck P.E. Jr, McElroy S.L., Shelton M.D.: A pilot study of topiramate as monotherapy in the treatment of acute mania. J. Clin. Psychopharmacol., 21, 340-342, 2001.
13. Bozikas V.P., Petrikis P., Kourtis A., Youlis P., Karavatos A.: Treatment of acute mania with topiramate in hospitalized patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 26, 1203-1206, 2002.
14. Arnone D.: Review of the use of Topiramate for treatment of psychiatric disorders. Ann. Gen. Psychiatry, 4, 5, 2005.
15. Kushner S.F., Khan A., Lane R., Olson W.H.: Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo controlled trials. Bipolar Disord., 8, 15-27, 2006.
16. Delbello N.R., Kushner S., Wang D., Olson W.H., Capece J.A., Fazzio L., Rosenthal N.R.: A pilot controlled trial of topiramate in mania in children and adolescents with bipolar disorder. J. Am. Acad. Child Psychiatry, 44, 259-547, 2005.
17. Vasudev K., Macritchie K., Geddes J., Watson S., Young A.: Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst. Rev., 25, CD003384, 2006.
18. Kusumakar V., Lakshmi N., Yatham M.B., O'Donovan C.A., Kutcher S.P.: Topiramate in rapid cycling bipolar women. In: 152nd Annual Meeting of the American Psychiatric Association, Washington, DC, 1999.
19. Marcotte D.: Use of Topiramate, a new anti-epileptic as a mood stabiliser. J. Affect. Disord., 50, 245-251, 1998.
20. McIntyre R.S., Riccardelli R., Bender C., Kusumakar V.: Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can. J. Psychiatry, 50, 415-422, 2005.
21. Vieta E., Torrent C., Garcia-Ribas G., Gilabert A., Garcia-Pares G., Rodriguez A., Cadevall J., Garcia-Castrillon J., Lusilla P., Arrufat F.: Use of topiramate in treatment-resistant bipolar spectrum disorders. J. Clin. Psychopharmacol., 22, 431-435, 2002.
22. Chengappa R.K.N., Rathore D., Levine J., Atzert R., Solai L., Parepally H., Levin H., Moffa N., Delaney J., Brar J.S.: Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord., 1, 42-53, 1999.
23. Grunze H.C., Normann C., Langosch J., Schaefer M., Amann B., Sterr A., Schloesser S., Kleindienst N., Walden J.: Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off design. J. Clin. Psychiatry, 62, 464-468, 2001.
24. McIntyre R.S., Konarski J.Z., Wilkins K., Soczynska J.K., Kennedy S.H.: Obesity in bipolar disorder and major depressive disorder: Results from a national community health survey on mental health and well-being. Can. J. Psychiatry, 51, 274-280, 2006.
25. Cassidy F., Ahearn E., Carroll B.J.: Elevated frequency of diabetes mellitus in hospitalized manic depressive patients. Am. J. Psychiatry, 156, 1417-1420, 1999.
26. Bray G.A., Hollander P., Klein S., Kushner R., Levy B., Fitchet M., Perry B.H.: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 11, 722-733, 2003.
27. M.I.N.I. SCREEN 5.0.0 / English version / DSM-IV 1/1/05 " 2001-2005 Sheehan DV & Lecrubier Y. All rights reserved. D. Sheehan, J. Janavs, R. Baker, (University of South Florida-Tampa, USA): Y. Lecrubier, T. Hergueta, E. Weiller, (INSERM-Paris, France). T. Proeschel.
28. National Institute of Mental Health. CGI: Clinica Global Impression. In: Guy W., Bonato R.R., (eds.), Manual for the ECDEU Assessment battery.2.Rev ed. Chevy Chase, MD, National Institute of Mental health, 1970, 12-1-12-6.
29. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A.: A rating scale for mania: reliability, validity, and sensitivity. Br. J. Psychiatry, 133, 429-435, 1978.
30. Hamilton M.: A rating scale for depression. J. Neurol. Neurosurg. Psychiatry, 23, 56-62, 1960.
31. Goldberg J.F., Burdick K.E.: Cognitive side effects of anticonvulsants. J. Clin. Psychiatry 62 (Suppl. 14), 27-33, 2001.
32. McIntyre R.S., Mancini D.A., MCann S., Srinivasan J., Sagman D., Kennedy S.H.: Topiramate versus bupropion SR, when added to a mood stabilizer therapy for depressive phases of bipolar disorder: a preliminary single-blind study. Bipolar Disord., 4, 207-213, 2002.
33. Carpenter L.L., Leon Z., Yasmin S., Price L.H.: Do obese depressed patients respond to topiramate? A retrospective chart review. J. Affect. Disord., 69, 251-255, 2002.
34. Colditz G.A., Willett W.C., Rotnitzky A., Manson J.E.: Weight gain as a risk factor for clinical diabetes in women. Ann. Intern. Med., 122, 122-486, 1995.
35. Hussain M.Z., Chaudhry Z.A., Hussain S.: Topiramate in treatment of refractory bipolar depression. Bipolar Disord. 3, 43, 2001.
36. Hoopes S.P., Reimherr F.W., Hedges D.W., Rosenthal N.R., Karim M., Karim R., Capece J.A., Karvois D.: treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1:improvement in binge and purge measures. J. Clin. Psychiatry, 64, 1335-1341, 2003.
37. McElroy S.L., Arnold L.M., Shapira N.A., Keck P.E., Rosenthal N.R., Karim M.R., KArim M., Hudson J.I.: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized placebo-controlled trial. Am. J. Psychiatry, 160, 255-261, 2003.
38. Bray G.A., Hollander P., Klein S., Kushner R., Levy B., Fitchet M., Perry B.H.: A 6 month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res., 11, 722-733, 2003.
39. Johnson B.A., Anita-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., Javors M.A., Ma J.Z.: Oral treatment for alcohol dependence: a randomized controlled trial. Lancet, 361, 1677-1685, 2003.
40. Brandes J.L., Saper J.R., Diamond M., Couch J.R., Lewis D.W., Schmitt J., Neto W., Schwabe S., Jacobs D.: Topiramate for migraine prevention: A randomized-controlled trial. JAMA, 29, 965-973, 2004.